Lutetium (177Lu) oxodotreotide - Wikipedia
Lutetium (177Lu) oxodotreotide (INN) or 177Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. [5] .
177Lu-DOTATATE for the treatment of gastroenteropancreatic
We discuss the role of 177 Lu-DOTATATE within the current treatment landscape for GEP NET patients. Expert Opinion: 177 Lu-DOTATATE represents a unique addition to the treatment armamentarium for GEP NETs because of its potential to elicit tumor cytoreduction, which is rare among other existing treatment options, and prolonged disease control.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine …
2017年1月12日 · Treatment with 177 Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut ...
Neuroendocrine Tumor Lu-177-Dotatate Therapy
2024年2月12日 · Lutetium-177 (177Lu)-dotatate therapy or peptide receptor radioligand therapy (PRRT) is indicated for treating gastroenteropancreatic neuroendocrine tumors and NET of the prostate gland. The FDA approved 177Lu-dotatate therapy in 2018 to treat somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.
Lutetium Lu 177-Dotatate - NCI - National Cancer Institute
Lutetium Lu 177-dotatate is approved to treat: Gastroenteropancreatic neuroendocrine tumors. It is used in adults and children aged 12 years and older whose cancer is somatostatin receptor positive. Lutetium Lu 177-dotatate is also being studied in the treatment of other types of cancer.
[177Lu]Lu-DOTA-TATE in newly diagnosed patients with …
2024年1月22日 · The Phase 3 NETTER-2 study (NCT03972488) evaluated [177 Lu]Lu-DOTA-TATE (hereafter 177 Lu-DOTATATE) as 1L treatment in pts with Grade (G) 2 and G3 advanced GEP-NETs. This is the first trial to assess 1L RLT in any solid tumor.
177Lu-DOTATATE for the treatment of gastroenteropancreatic ...
177 Lu-DOTATATE is a radiolabeled somatostatin agonist (SSA), which is approved for the treatment of somatostatin receptor positive well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients in Europe, the United States, and Canada.
Neuroendocrine Tumor Therapy: 177Lu-DOTATATE - AJR
2018年6月27日 · The FDA approval of 177 Lu-DOTATATE is for the treatment of SSTR-positive gastroenteropancreatic NETs, including foregut, midgut, and hindgut NETs in adults (package insert, Advanced Accelerator Applications). The primary considerations in patient selection for this therapy are tumor grade, SSTR density based on nuclear imaging findings ...
Neuroendocrine Tumor Therapy: 177Lu-DOTATATE - PubMed
In January 2018, 177 Lu-DOTATATE therapy was approved in the United States (previously approved in Europe in September 2017) for adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including those of …
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide
177 Lu-DOTATATE is a radiolabeled somatostatin analog that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults.